SPRY

Ars Pharmaceuticals Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↓ 2/10
  • Value↓ 4/10
Ars Pharmaceuticals sales and earnings growth
SPRY Growth
Fair
  • Revenue Y/Y↓ 0.71%
  • EPS Y/Y↓ -1082.35%
  • FCF Y/Y↓ -732.67%
Ars Pharmaceuticals gross and profit margin trends
SPRY Profitability
Fair
  • Gross margin ↑ 74.10%
  • EPS margin↓ -200.00%
  • ROIC 5Y↓ -29.92%
Ars Pharmaceuticals net debt vs free cash flow
SPRY Risk
Fair
  • Debt / Equity↑ 2.8
  • Debt / FCF↓ 0.8
  • Interest coverage↓ -38.3

Ars Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Fair risk rating.

↗ More Biotechnology stocks